Effect and mechanism of baicalin on antipsychotic drug-induced obesity

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800016727

Enrollment

Unknown

Registered

2018-06-20

Start date

2016-01-01

Completion date

Unknown

Last updated

2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

1:baicalin 0.75g,tid, po

2:baicalin 0.50g,tid, po

3:baicalin 0.25g,tid, po

4:Placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. diagnosis of first episode schizophrenia based on the Diagnostic and Statistical Manual of Mental Disorders fourth version (DSM-IV) criteria and confirmed using the Structured Clinical Interview for DSM-IV (SCID) 2. has never been on antipsychotic medication before; 3. the PANSS total score >70 points 4. aged between 18 and 60; 5. no allergy to baicalin; 6. the weight increased by more than 7% after risperidone or olanzapine treatment compared with the baseline; 7. informed consent of patients and their families.

Exclusion criteria

Exclusion criteria: 1. diagnoses of autoimmune diseases, heartdiseases, hepatobiliary and gastrointestinal diseases, blood diseases, diabetes neurological diseases, or psychiatric diseases other than first episode schizophrenia; 2. a history of allergy and hormone therapy, and have received immunotherapy in the past month; 3. a history of using any antibiotic or anti-inflammatory agent in the past month; 4. pregnant or lactating women; 5. do not agree to participate in the study.

Design outcomes

Primary

Measure	Time frame
PANSS score;cognitive function;Glycolipid metabolites;	—

Countries

China

Contacts

Public ContactXueqin Song

The First Affiliated Hospital of Zhengzhou University

sxqzhll@126.com+86 13513895052

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026